[Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder].
Sarcomatoid bladder carcinoma is a high-grade neoplasm and accounts for approximately 0,3% of all bladder malignancies. Sarcomatoid carcinoma originates from transitional cells of the bladder. Sarcomatoid carcinoma is charactericed by a epithelial component and a sarcomatoid component, consisting of spindle cells, that is only epithelial marker-positive. We report a 26-year-old woman diagnosed of stage III sarcomatoid bladder carcinoma (T3aN0M0) treated with partial cistectomy followed by 4 cycles of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.
García González
Jorge
J
Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, España. jorgejgglez@yahoo.es
Pérez Fentes
Daniel
D
Aliste Santos
Carlos
C
Suárez Peñaranda
José M
JM
León Mateos
Luis
L
López López
Rafael
R
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014747:Vinblastine / Q000627:therapeutic use
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate